Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
49
FBLG Quote, Financials, Valuation and Earnings
Last price:
$0.33
Seasonality move
:
-54.09%
Day range:
$0.26 - $0.37
52-week range:
$0.22 - $2.28
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
141.57x
Volume:
6M
Avg. volume:
2.9M
1-year change:
-84.78%
Market cap:
$17.7M
Revenue:
--
EPS (TTM):
-$0.48
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
FBLG
FibroBiologics, Inc.
|
-- | -$0.10 | -- | -9.77% | $8.13 |
|
INBS
Intelligent Bio Solutions, Inc.
|
$1.4M | -- | 160.36% | -- | -- |
|
ISPC
iSpecimen, Inc.
|
$2.9M | -- | 6.09% | -- | -- |
|
SLS
SELLAS Life Sciences Group, Inc.
|
-- | -$0.06 | -- | -30.48% | $6.83 |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$59.3M | -- | 11.45% | -- | $13.13 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
FBLG
FibroBiologics, Inc.
|
$0.34 | $8.13 | $17.7M | -- | $0.00 | 0% | -- |
|
INBS
Intelligent Bio Solutions, Inc.
|
$11.84 | -- | $11.4M | -- | $0.00 | 0% | 23.54x |
|
ISPC
iSpecimen, Inc.
|
$0.31 | -- | $3M | -- | $0.00 | 0% | 0.27x |
|
SLS
SELLAS Life Sciences Group, Inc.
|
$4.04 | $6.83 | $575.5M | -- | $0.00 | 0% | -- |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$8.54 | $13.13 | $504.7M | -- | $0.00 | 0% | 2.37x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
FBLG
FibroBiologics, Inc.
|
98.27% | -0.223 | 26.98% | 0.72x |
|
INBS
Intelligent Bio Solutions, Inc.
|
35.02% | 2.237 | 21.48% | 0.47x |
|
ISPC
iSpecimen, Inc.
|
8.39% | 3.440 | 2.23% | 0.62x |
|
SLS
SELLAS Life Sciences Group, Inc.
|
1.3% | 0.623 | 0.3% | 7.50x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
2.29% | -0.960 | 3.7% | 2.92x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
FBLG
FibroBiologics, Inc.
|
-$231K | -$5M | -201.42% | -1050.36% | -- | -$4M |
|
INBS
Intelligent Bio Solutions, Inc.
|
$214.9K | -$2.9M | -213.68% | -255.54% | -263.64% | -$2.9M |
|
ISPC
iSpecimen, Inc.
|
-$555.7K | -$2.8M | -365.92% | -430.7% | -2654.97% | -$3M |
|
SLS
SELLAS Life Sciences Group, Inc.
|
-- | -$7.1M | -100.8% | -103.86% | -- | -$7.1M |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$51.6M | -$31.3M | -16.2% | -16.55% | -55.61% | -$31.8M |
FibroBiologics, Inc. vs. Competitors
-
Which has Higher Returns FBLG or INBS?
Intelligent Bio Solutions, Inc. has a net margin of -- compared to FibroBiologics, Inc.'s net margin of -269.38%. FibroBiologics, Inc.'s return on equity of -1050.36% beat Intelligent Bio Solutions, Inc.'s return on equity of -255.54%.
Company Gross Margin Earnings Per Share Invested Capital FBLGFibroBiologics, Inc.-- -$0.13 $7.2M INBSIntelligent Bio Solutions, Inc.19.33% -$0.35 $5.4M -
What do Analysts Say About FBLG or INBS?
FibroBiologics, Inc. has a consensus price target of $8.13, signalling upside risk potential of 2262.61%. On the other hand Intelligent Bio Solutions, Inc. has an analysts' consensus of -- which suggests that it could grow by 913.51%. Given that FibroBiologics, Inc. has higher upside potential than Intelligent Bio Solutions, Inc., analysts believe FibroBiologics, Inc. is more attractive than Intelligent Bio Solutions, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FBLGFibroBiologics, Inc.2 0 0 INBSIntelligent Bio Solutions, Inc.0 0 0 -
Is FBLG or INBS More Risky?
FibroBiologics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intelligent Bio Solutions, Inc. has a beta of 4.455, suggesting its more volatile than the S&P 500 by 345.491%.
-
Which is a Better Dividend Stock FBLG or INBS?
FibroBiologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. FibroBiologics, Inc. pays -- of its earnings as a dividend. Intelligent Bio Solutions, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FBLG or INBS?
FibroBiologics, Inc. quarterly revenues are --, which are smaller than Intelligent Bio Solutions, Inc. quarterly revenues of $1.1M. FibroBiologics, Inc.'s net income of -$5.8M is lower than Intelligent Bio Solutions, Inc.'s net income of -$3M. Notably, FibroBiologics, Inc.'s price-to-earnings ratio is -- while Intelligent Bio Solutions, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for FibroBiologics, Inc. is -- versus 23.54x for Intelligent Bio Solutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FBLGFibroBiologics, Inc.-- -- -- -$5.8M INBSIntelligent Bio Solutions, Inc.23.54x -- $1.1M -$3M
-
Which has Higher Returns FBLG or ISPC?
iSpecimen, Inc. has a net margin of -- compared to FibroBiologics, Inc.'s net margin of -2608.44%. FibroBiologics, Inc.'s return on equity of -1050.36% beat iSpecimen, Inc.'s return on equity of -430.7%.
Company Gross Margin Earnings Per Share Invested Capital FBLGFibroBiologics, Inc.-- -$0.13 $7.2M ISPCiSpecimen, Inc.-521.3% -$0.48 $3.4M -
What do Analysts Say About FBLG or ISPC?
FibroBiologics, Inc. has a consensus price target of $8.13, signalling upside risk potential of 2262.61%. On the other hand iSpecimen, Inc. has an analysts' consensus of -- which suggests that it could grow by 19205.02%. Given that iSpecimen, Inc. has higher upside potential than FibroBiologics, Inc., analysts believe iSpecimen, Inc. is more attractive than FibroBiologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FBLGFibroBiologics, Inc.2 0 0 ISPCiSpecimen, Inc.0 0 0 -
Is FBLG or ISPC More Risky?
FibroBiologics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iSpecimen, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock FBLG or ISPC?
FibroBiologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iSpecimen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. FibroBiologics, Inc. pays -- of its earnings as a dividend. iSpecimen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FBLG or ISPC?
FibroBiologics, Inc. quarterly revenues are --, which are smaller than iSpecimen, Inc. quarterly revenues of $106.6K. FibroBiologics, Inc.'s net income of -$5.8M is lower than iSpecimen, Inc.'s net income of -$2.8M. Notably, FibroBiologics, Inc.'s price-to-earnings ratio is -- while iSpecimen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for FibroBiologics, Inc. is -- versus 0.27x for iSpecimen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FBLGFibroBiologics, Inc.-- -- -- -$5.8M ISPCiSpecimen, Inc.0.27x -- $106.6K -$2.8M
-
Which has Higher Returns FBLG or SLS?
SELLAS Life Sciences Group, Inc. has a net margin of -- compared to FibroBiologics, Inc.'s net margin of --. FibroBiologics, Inc.'s return on equity of -1050.36% beat SELLAS Life Sciences Group, Inc.'s return on equity of -103.86%.
Company Gross Margin Earnings Per Share Invested Capital FBLGFibroBiologics, Inc.-- -$0.13 $7.2M SLSSELLAS Life Sciences Group, Inc.-- -$0.06 $46.2M -
What do Analysts Say About FBLG or SLS?
FibroBiologics, Inc. has a consensus price target of $8.13, signalling upside risk potential of 2262.61%. On the other hand SELLAS Life Sciences Group, Inc. has an analysts' consensus of $6.83 which suggests that it could grow by 69.14%. Given that FibroBiologics, Inc. has higher upside potential than SELLAS Life Sciences Group, Inc., analysts believe FibroBiologics, Inc. is more attractive than SELLAS Life Sciences Group, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FBLGFibroBiologics, Inc.2 0 0 SLSSELLAS Life Sciences Group, Inc.2 0 0 -
Is FBLG or SLS More Risky?
FibroBiologics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison SELLAS Life Sciences Group, Inc. has a beta of 2.262, suggesting its more volatile than the S&P 500 by 126.208%.
-
Which is a Better Dividend Stock FBLG or SLS?
FibroBiologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SELLAS Life Sciences Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. FibroBiologics, Inc. pays -- of its earnings as a dividend. SELLAS Life Sciences Group, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FBLG or SLS?
FibroBiologics, Inc. quarterly revenues are --, which are smaller than SELLAS Life Sciences Group, Inc. quarterly revenues of --. FibroBiologics, Inc.'s net income of -$5.8M is higher than SELLAS Life Sciences Group, Inc.'s net income of -$6.8M. Notably, FibroBiologics, Inc.'s price-to-earnings ratio is -- while SELLAS Life Sciences Group, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for FibroBiologics, Inc. is -- versus -- for SELLAS Life Sciences Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FBLGFibroBiologics, Inc.-- -- -- -$5.8M SLSSELLAS Life Sciences Group, Inc.-- -- -- -$6.8M
-
Which has Higher Returns FBLG or VNDA?
Vanda Pharmaceuticals, Inc. has a net margin of -- compared to FibroBiologics, Inc.'s net margin of -40.15%. FibroBiologics, Inc.'s return on equity of -1050.36% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.
Company Gross Margin Earnings Per Share Invested Capital FBLGFibroBiologics, Inc.-- -$0.13 $7.2M VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M -
What do Analysts Say About FBLG or VNDA?
FibroBiologics, Inc. has a consensus price target of $8.13, signalling upside risk potential of 2262.61%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $13.13 which suggests that it could grow by 53.69%. Given that FibroBiologics, Inc. has higher upside potential than Vanda Pharmaceuticals, Inc., analysts believe FibroBiologics, Inc. is more attractive than Vanda Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FBLGFibroBiologics, Inc.2 0 0 VNDAVanda Pharmaceuticals, Inc.3 1 0 -
Is FBLG or VNDA More Risky?
FibroBiologics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.604, suggesting its less volatile than the S&P 500 by 39.647%.
-
Which is a Better Dividend Stock FBLG or VNDA?
FibroBiologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. FibroBiologics, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FBLG or VNDA?
FibroBiologics, Inc. quarterly revenues are --, which are smaller than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. FibroBiologics, Inc.'s net income of -$5.8M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, FibroBiologics, Inc.'s price-to-earnings ratio is -- while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for FibroBiologics, Inc. is -- versus 2.37x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FBLGFibroBiologics, Inc.-- -- -- -$5.8M VNDAVanda Pharmaceuticals, Inc.2.37x -- $56.3M -$22.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
70
RGC alert for Jan 8
Regencell Bioscience Holdings Ltd. [RGC] is down 21.5% over the past day.
Buy
64
RVMD alert for Jan 8
Revolution Medicines, Inc. [RVMD] is up 4.61% over the past day.
Sell
38
CRNX alert for Jan 8
Crinetics Pharmaceuticals, Inc. [CRNX] is down 0.23% over the past day.
